Anita Bellail
CEO HB Therapeutics, Inc.
Seminars
Wednesday 28th October 2026
Molecular Glue Degrader–Induced Co-Degradation of Mutant KRAS & CRAF Drives In Vivo Responses
4:30 pm
- Discovery and optimization of a molecular glue degrader targeting mutant KRAS and CRAF
- Mechanism of action and structural basis of induced co-degradation
- In vivo efficacy and therapeutic potential in KRAS-mutant models
